Haemonetics (HAE) Tops Q2 EPS by 7c, Beats on Revenues

Haemonetics (NYSE: HAE) reported Q2 EPS of $0.48, $0.07 better than the analyst estimate of $0.41. Revenue for the quarter came in at $225 million versus the consensus estimate of $219.26 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c